Interní Med. 2006; 8(7): 330-335

Ace inhibitors with dual elimination pathway

MUDr. Vlastimil Ráček
II. interní klinika FN u sv. Anny LF MU, Brno

Most ACE inhibitors (ACE-I) and their metabolites are mainly excreted by the renal route, whereas fosinopril, trandolapril, spirapril, moexipril and ramipril display elimination through hepatic and renal routes and have dual elimination pathway. For most ACE inhibitors, dosage adjustment is recommended in moderate and severe impairment of renal function. Dosage recommendation for treatment depend on the specific pharmacokinetics properties of the various ACE-I.

Keywords: Key words: ACE inhibitors, pharmacokinetics, hypertension.

Published: June 1, 2006  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Ráček V. Ace inhibitors with dual elimination pathway. Interní Med. 2006;8(7):330-335.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Carter BL Dosing of antihypertensive medication in patients with renal insufficiency. J Clin Pharmacol 1995; 35: 81-86.
    2. Elston AC, Bayliss MK, Park GR Effect of renal failure on drug metabolism by the liver. British journal of anaesthesie 1993; 71: 282-290. Go to original source... Go to PubMed...
    3. Fischler MO, Follah F Comparative evaluation of ACE inhibitors: Which differences are relevant? Schweiz Med. Wochenschr 1999; 129: 1053-1060. Go to PubMed...
    4. Furberg CD Class effect and evidence-based medicine. Clin Cardiology 200; 23 (Supl. IV): 15-19.
    5. Grass P, Gerbeau C, Kutz K Spirapril: Pharmacokinetic properties and drug interactions. Blood Pressure 1994; 3 (Suppl 2): 7-13. Go to PubMed...
    6. Hoyer J, Schulte KL, Lennz T Clnical pharmacokinetics of angiotensin converting enzyme (AC) inhibitors in renal failure. Clin Pharmacokinet 1993; 24: 230-254. Go to original source... Go to PubMed...
    7. Hui KK, Duchin KL, Kripalani KJ Pharmacokinetics of fosinopril in patients with various degrees of renal function. Clin Pharmacil Ther 1991; 49: 457-467. Go to original source... Go to PubMed...
    8. Jardine AG, Elliot HL ACE inhibition in chronic renal failure and treatment of diabetic nephropathy: focus on spirapril. Journal of cardiovascular pharmacology 1999; 34: 31-34. Go to original source... Go to PubMed...
    9. Leonetti G, Cuspidi C Choosing the right ACE inhibitor. Drugs 1995; 49: 516-535. Go to original source... Go to PubMed...
    10. Lopez J, Swedberg K, McMurray J, et al. Expert consensus document on angiotensin convertin enzyme inhibitors in cardiovascular disease. European Heart Journal 2004; 25: 1454-1470. Go to original source... Go to PubMed...
    11. Noble S, Sorkin EM Spirapril a preliminary review of its pharmacology and therapeutic efficacy in the treatment of hypertension. Drugs 1995; 49: 750-766. Go to original source... Go to PubMed...
    12. Sica DA, Culter RE, Parmer RJ et al. Comparison of the steady-state pharmacokinetics of fosinopril, lisinopril and enalapril in patiens with chronic renal insufficiency. Clin Pharmacokinet 1991; 20: 420-427. Go to original source... Go to PubMed...
    13. Schunkert H, Kindler J, Gassmann M Pharmacokinetics of ramipril in hypertensive patients with renal insufficiency. Eur J Clin Pharmacol 1989; 37: 249-256. Go to original source... Go to PubMed...
    14. Song JC, White MC Clinical pharmacokinetics and selective pharmacodynamics of new angiotensin converteing enzyme inhibitors. Clin Pharmacokinet 2002; 41, 207-224. Go to original source... Go to PubMed...
    15. Souhrn údajů o přípravku Monopril, datum revize textu 17. 12. 2003.
    16. Souhrn údajů o přípravku Renpress, datum revize textu 31. 3. 2004.
    17. Souhrn údajů o přípravku Tritace, datum revize textu 2. 6. 2004.
    18. Souhrn údajů o přípravku Moex, datum revize textu 9. 7. 2003.
    19. Souhrn údajů o přípravku Gopten, datum revize textu 10. 9. 2003.
    20. Stein G, Sierakowski B, Grass P Pharmacokinetics of spirapril and spiraprilat in patients with chronic renal failure. Blood pressure 1994; 3 (Supl 2): 47-53. Go to PubMed...
    21. Stein G, Sierakowski B, Jansa U Spirapril in chronic renal failure. Blood pressure 1994; 3 (Suppl 2): 54-60.
    22. White CM Pharmacologic, pharmacokinetic and therapeutic differences among ACE inhibitors. Pharmacotherapy 1998; 3: 588-599.
    23. Widimský J Selhání srdce - stručná verze 2002 Praha; Triton 2002: 116-117.

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.